Actively Recruiting
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Led by Federation Francophone de Cancerologie Digestive · Updated on 2025-08-05
150
Participants Needed
40
Research Sites
260 weeks
Total Duration
On this page
Sponsors
F
Federation Francophone de Cancerologie Digestive
Lead Sponsor
S
Société Nationale Française de Gastroentérologie
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to describe the clinical, histological, and radiological features of rare primary liver cancers. It focuses on collecting tumor and blood samples to better understand these cancers and to evaluate how well treatments used in real-world practice work, with the goal of identifying the best treatment sequences. The study serves as a foundation for future research to find new molecular and imaging biomarkers that could improve diagnosis and prognosis. The study is observational and retrospective, meaning it reviews past cases from multiple centers in France. It collects biological samples and clinical data from patients diagnosed with rare primary liver cancers after January 2018. The study evaluates treatments patients have received in clinical practice without assigning any new treatments or interventions. Participants data, including clinical characteristics, tumor biology, and imaging, will be reviewed for up to five years from diagnosis. Researchers will measure outcomes such as recurrence-free survival for patients without metastases, progression-free survival for those with metastases, and overall survival. The study includes both living patients who consent to participate and deceased patients, aiming to gather comprehensive information to support future translational studies.
CONDITIONS
Brief Title
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Histologically confirmed diagnosis of hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, or hepatic angiosarcoma
- Diagnosed on or after January 1, 2018
- Living or deceased at the time of registration
- Living patients who have not objected to research and agree to participate in biological studies by signing consent
You will not qualify if you...
- No social security coverage
- No access to tumor tissue samples (tumor block)
Research Team
L
lila gaba
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here